MCID: ANV001
MIFTS: 49

Anovulation

Categories: Endocrine diseases, Reproductive diseases

Aliases & Classifications for Anovulation

MalaCards integrated aliases for Anovulation:

Name: Anovulation 12 55 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:3781
MeSH 44 D000858
NCIt 50 C34388
SNOMED-CT 68 34571000
UMLS 73 C0003128

Summaries for Anovulation

Disease Ontology : 12 An ovarian disease that is characterized by the absence of ovulation.

MalaCards based summary : Anovulation is related to polycystic ovary syndrome and infertility. An important gene associated with Anovulation is SHBG (Sex Hormone Binding Globulin), and among its related pathways/superpathways are Development Endothelin-1/EDNRA signaling and Prolactin Signaling Pathway. The drugs Metformin and Letrozole have been mentioned in the context of this disorder. Affiliated tissues include ovary, pituitary and endothelial, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 76 Anovulation is when the ovaries do not release an oocyte during a menstrual cycle. Therefore, ovulation... more...

Related Diseases for Anovulation

Diseases related to Anovulation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 139)
# Related Disease Score Top Affiliating Genes
1 polycystic ovary syndrome 31.4 CYP19A1 FSHR GNRH1 IGF1 INS LEP
2 infertility 30.4 CYP19A1 FSHB FSHR GNRH1 PRL
3 premenstrual tension 30.3 GNRH1 PRL SHBG
4 hyperprolactinemia 30.2 GNRH1 IGF1 PRL SHBG
5 hyperandrogenism 29.9 CYP19A1 GNRH1 IGF1 INS PRL SHBG
6 amenorrhea 29.8 BMP15 FSHB FSHR GNRH1 LEP PRL
7 hyperinsulinism 29.7 IGF1 INS LEP SHBG
8 diabetes mellitus 29.5 CRP IGF1 INS LEP SHBG
9 hypothyroidism 29.4 FSHR IGF1 LEP PRL SHBG
10 glucose intolerance 29.3 CRP IGF1 INS LEP SHBG
11 ovarian disease 29.1 BMP15 CGA CYP19A1 FSHR GNRH1 IGF1
12 resistance to lh 11.1
13 chiasmal syndrome 10.2 GNRH1 PRL
14 hyperproinsulinemia 10.2 INS SHBG
15 hypoactive sexual desire disorder 10.2 CYP19A1 SHBG
16 seborrheic dermatitis 10.2 CGA SHBG
17 hypogonadotropism 10.2 GNRH1 PRL
18 hypothalamic disease 10.2 GNRH1 PRL
19 androgen insensitivity, partial 10.2 CYP19A1 SHBG
20 luteoma 10.2 CGA CYP19A1
21 secondary adrenal insufficiency 10.2 IGF1 INS
22 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.2 IGF1 INS
23 pseudovaginal perineoscrotal hypospadias 10.2 CGA GNRH1
24 alopecia, androgenetic, 1 10.2 CYP19A1 SHBG
25 galactorrhea 10.2 IGF1 PRL
26 endometriosis 10.2
27 marasmus 10.2 IGF1 SHBG
28 fetal erythroblastosis 10.2 INS SHBG
29 pseudohypoparathyroidism, type ia 10.2 IGF1 PRL
30 hypogonadotropic hypogonadism 23 without anosmia 10.2 FSHR GNRH1
31 tsh producing pituitary tumor 10.2 GNRH1 PRL
32 donohue syndrome 10.2 IGF1 INS
33 pelvic varices 10.2 GNRH1 PRL SHBG
34 lipodystrophy, familial partial, type 1 10.1 INS LEP
35 pituitary apoplexy 10.1 GNRH1 INS PRL
36 precocious puberty, male-limited 10.1 CYP19A1 FSHR
37 complete androgen insensitivity syndrome 10.1 CGA CYP19A1 SHBG
38 chromophobe adenoma 10.1 GNRH1 INS PRL
39 pituitary-dependent cushing's disease 10.1 GNRH1 INS PRL
40 freemartinism 10.1 BMP15 GNRH1
41 complete generalized lipodystrophy 10.1 INS LEP
42 male reproductive system disease 10.1 GNRH1 IGF1 SHBG
43 stuttering 10.1 CYP19A1 GNRH1 SHBG
44 androgenic alopecia 10.1 CYP19A1 PRL SHBG
45 aromatase deficiency 10.1 CYP19A1 GNRH1 INS
46 sebaceous gland disease 10.1 IGF1 SHBG
47 breast cancer 10.1
48 abdominal obesity-metabolic syndrome 1 10.1 INS LEP
49 lipodystrophy, congenital generalized, type 1 10.1 INS LEP
50 male reproductive organ cancer 10.1 GNRH1 IGF1 SHBG

Graphical network of the top 20 diseases related to Anovulation:



Diseases related to Anovulation

Symptoms & Phenotypes for Anovulation

GenomeRNAi Phenotypes related to Anovulation according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.62 IGF1 LEP
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-112 9.62 LEP
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.62 IGF1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.62 IGF1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-144 9.62 IGF1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.62 IGF1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 9.62 SHBG
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 9.62 IGF1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-20 9.62 BMP15
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.62 IGF1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.62 BMP15 IGF1 LEP SHBG
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.62 LEP
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.62 IGF1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.62 LEP
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.62 IGF1
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.62 BMP15

MGI Mouse Phenotypes related to Anovulation:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.17 AMHR2 BMP15 CGA CYP19A1 FSHB FSHR
2 homeostasis/metabolism MP:0005376 10.14 AMHR2 CGA CRP CYP19A1 FSHB FSHR
3 immune system MP:0005387 10.02 AMHR2 CRP CYP19A1 FSHR GNRH1 IGF1
4 cardiovascular system MP:0005385 10 AMHR2 CRP CYP19A1 FSHR IGF1 INS
5 integument MP:0010771 9.92 AMHR2 CYP19A1 FSHR GNRH1 IGF1 INS
6 adipose tissue MP:0005375 9.88 CYP19A1 FSHR IGF1 INS LEP
7 nervous system MP:0003631 9.76 CGA CYP19A1 FSHR GNRH1 IGF1 INS
8 neoplasm MP:0002006 9.73 AMHR2 FSHR GNRH1 IGF1 LEP PRL
9 renal/urinary system MP:0005367 9.43 AMHR2 CYP19A1 GNRH1 IGF1 INS LEP
10 reproductive system MP:0005389 9.36 AMHR2 BMP15 CGA CYP19A1 FSHB FSHR

Drugs & Therapeutics for Anovulation

Drugs for Anovulation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 657-24-9 14219 4091
2
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 112809-51-5 3902
3
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
4
Ethinyl Estradiol Approved Phase 4,Not Applicable 57-63-6 5991
5
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Early Phase 1,Not Applicable 50-28-2 5757
6
Polyestradiol phosphate Approved Phase 4,Phase 3,Early Phase 1,Not Applicable 28014-46-2
7 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Early Phase 1,Not Applicable 979-32-8
8
Zinc Approved, Investigational Phase 4,Early Phase 1 7440-66-6
9
Menotropins Approved Phase 4,Phase 1,Phase 2,Not Applicable 61489-71-2, 9002-68-0 5360545
10
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
11
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Not Applicable 71-58-9
12
leucovorin Approved Phase 4,Not Applicable 58-05-9 6006 143
13
Acetylcysteine Approved, Investigational Phase 4,Not Applicable 616-91-1 12035
14
Drospirenone Approved Phase 4 67392-87-4 68873
15 Piracetam Approved, Investigational Phase 4 7491-74-9
16
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 77-92-9 311
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 59-30-3 6037
18
Enclomiphene Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 15690-57-0
19 Etiracetam Investigational Phase 4 33996-58-6
20 Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Estrogen Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Selective Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Anticoagulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Chelating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
31 Citrate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Zuclomiphene Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Clomiphene Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Fertility Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
37 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
38 Androgen Antagonists Phase 4,Phase 2,Not Applicable
39 Contraceptive Agents Phase 4,Phase 3,Not Applicable
40
Cyproterone Phase 4 2098-66-0 5284537
41 Androgens Phase 4,Phase 2,Not Applicable,Early Phase 1
42 Contraceptives, Oral Phase 4,Phase 3,Not Applicable
43 Contraceptive Agents, Male Phase 4,Phase 3,Not Applicable
44 Progestins Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
45 Tin Fluorides Phase 4,Phase 3
46 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
47 insulin Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
48 Estradiol 3-benzoate Phase 4,Phase 3,Early Phase 1,Not Applicable
49 Estradiol 17 beta-cypionate Phase 4,Phase 3,Early Phase 1,Not Applicable
50 Contraceptives, Oral, Combined Phase 4

Interventional clinical trials:

(show top 50) (show all 164)
# Name Status NCT ID Phase Drugs
1 Strategies for Ovulation Induction in Anovulatory Infertile Patients With PCOS Unknown status NCT00461643 Phase 4 Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins
2 Administration of Single High Dose Letrozole for Ovulation Induction Unknown status NCT02703649 Phase 4 Letrozole
3 Endometrial Scratching During Laproscopic Ovarian Drilling in Subfertile PCOS Women Unknown status NCT02140398 Phase 4
4 Metformin in Infertile PCOS Patients Unknown status NCT00501904 Phase 4 Metformin
5 PCOS, Therapy and Markers of Cardiovascular Risk Unknown status NCT01798875 Phase 4 oral metformin;oral contraceptive
6 Gonadotrophin Dosage Using a Threshold Nomogram for Ovulation Induction in WHO Group II Anovulatory Infertility Completed NCT01250821 Phase 4 Menopur
7 Treatment of Anovulatory Infertility in PCOS Patients Completed NCT00471523 Phase 4 Clomiphene citrate;Metformin
8 Second-Line Treatments for Anovulatory Infertility in PCOS Patients Completed NCT00558077 Phase 4 Metformin plus clomiphene citrate
9 Structured Exercise Training Program Versus Hypocaloric Hyperproteic Diet in Obese Anovulatory Infertile Patients With PCOS Completed NCT00473538 Phase 4
10 Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction Completed NCT01081626 Phase 4 Recombinant FSH (follitropin alpha)
11 PCOSMIC Trial - PolyCystic Ovary Syndrome, Metformin for Infertility With Clomiphene Completed NCT00795808 Phase 4 Metformin;Placebo;Metformin + Clomiphene;Metformin;Clomiphene
12 Endometrial Shedding Prior to Ovulation Induction Pilot Study Completed NCT02340013 Phase 4 Medroxyprogesterone acetate
13 Short-term Structured Exercise Training Program Plus Diet Intervention in Patients With Polycystic Ovary Syndrome (PCOS) Completed NCT01004068 Phase 4 Clomiphene citrate
14 Metformin and Folate Supplementation in Polycystic Ovary Syndrome (PCOS) Patients Completed NCT00953355 Phase 4 Folate plus metformin;Placebo plus metformin
15 "Stair Step Study" Completed NCT03309176 Phase 4 Medroxyprogesterone Acetate 10 MG
16 N-acetyl Cysteine for Ovulation Induction in Clomiphene Citrate Resistant Polycystic Ovary Syndrome Completed NCT02239107 Phase 4 N-Acetyl cysteine
17 Adding L-Carnitine to Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome Completed NCT03630341 Phase 4 Clomiphene Citrate 50mg;L-carnitine;Placebo Oral Tablet
18 The Effects of OCP and Metformin on Clinical, Hormonal, Metabolic and Ultrasonographic Characteristics in PCOS Completed NCT02866786 Phase 4 Metformin;ethinyl estradiol and cyproterone acetate
19 Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism Completed NCT01360996 Phase 4 3 mg DRSP/20 μg EE
20 Clomiphene Plus N-acetyl Cysteine for Induction of Ovulation in Newly Diagnosed Pcos. Completed NCT01896492 Phase 4 NAC
21 The Effect of Metformin on Different Hormones in PCOS Patients Completed NCT02568488 Phase 4 Metformin
22 Metformin Suspension and Insulin Sensitivity Completed NCT00437333 Phase 4 Metformin cloridrate
23 Aromatase Inhibitor Effects on Ovarian Function During the Follicular and Early Luteal Phase in Women Completed NCT01046578 Phase 4 Letrozole;Letrozole;Letrozole;Letrozole;Letrozole;Letrozole
24 Letrozole Versus Clomifene Citrate for Ovulation Induction Completed NCT00478504 Phase 4 Letrozole;Clomifene citrate
25 Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy Completed NCT00630630 Phase 4 Levetiracetam
26 Ovarian Response to Recombinant Follicle Stimulating Hormone in Women With PCOS Recruiting NCT03252223 Phase 4 Recombinant Follicle Stimulating Hormone
27 Concomitant CC and E2 Versus CC Alone in Ovulation Induction Recruiting NCT02186782 Phase 4 Clomiphene citrate and Estradiol;Clomiphene citrate and Placebo
28 Endometrial Thickness and Subendometrial Vascularity in Anovulatory Polycystic Ovarian Syndrome Patients Treated by Metformin Active, not recruiting NCT03486626 Phase 4 Metformin
29 Controlled Ovarian Stimulation Followed by Timed Intercourse or Intrauterine Insemination in Infertile PCOS Patients Suspended NCT00502281 Phase 4 highly purified urinary FSH
30 Pilot Study:Role of Dietary Fiber in PCOS Anovulation Terminated NCT00703092 Phase 4 Fiber-Stat
31 Low-dose Gonal-f® in Ovulation Induction Terminated NCT01871532 Phase 4 Gonal-f®
32 Metformin in Assisted Reproduction-MET-AR-study Terminated NCT00159575 Phase 4 Metformin / Placebo treatment for 4 months
33 Metformin Administration in Infertile Anovulatory PCOS Patients Withdrawn NCT00501787 Phase 4 Metformin
34 Clomiphene Citrate in Infertile PCOS Patients Withdrawn NCT00501839 Phase 4 clomiphene citrate
35 Therapy for Infertile PCOS Patients Ovulating Under Clomiphene Citrate or Metformin Withdrawn NCT00502229 Phase 4 Clomiphene citrate, metformin, highly purified urinary FSH
36 The Clinical Trial of Acupuncture Pre-treatment on PCOS Unknown status NCT02491320 Phase 3 Letrozole
37 Phase III Clinical Study of Domestic Recombinant Human Follitropin for Injection to Treat WHO Class II Anovulation Completed NCT02335879 Phase 3
38 Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women Completed NCT01653743 Phase 3 MSJ-0011;urinary hCG (u-hCG);Follitropin alpha
39 A Phase III Clinical Study to Compare the Efficacy and Safety of DA-3801 and That of Gonal-F® Completed NCT01820728 Phase 3 DA-3801 Injection;Gonal-F®
40 The Effect of Metformin Added to Clomiphene Citrate on Pregnancy Rates in Hyperandrogenic, Chronic Oligoovulatory or Anovulatory Women Completed NCT00413179 Phase 3 Metformin;Clomiphene citrate;Placebo
41 Letrozole vs. Clomiphene Citrate in Patients With Anovulatory Infertility Completed NCT00610077 Phase 3 Letrozole;Clomiphene citrate
42 Evaluation of Efficacy and Safety of Highly Purified Urofollitropin for Ovulation Induction in Chinese Females Completed NCT01923194 Phase 3 Highly Purified Urofollitropin;Recombinant Human Follitropin Alfa
43 Traditional Clomiphene Citrate Administration vs. Stair-step Approach Completed NCT01008319 Phase 3 clomiphene citrate;clomiphene citrate
44 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Completed NCT00296465 Phase 2, Phase 3 Pulsatile gonadotropin-releasing hormone (GnRH);Clomiphene Citrate;Placebo Pulsatile GnRH;Placebo Clomiphene Citrate
45 SJ-0021 (Gonalef®) Versus Purified Pituitary Gonadotropin (Fertinorm-P®) for Ovulation Induction in Japanese Infertile Women Completed NCT01185782 Phase 3 Gonalef® (Follitropin alfa);Purified pituitary gonadotropin (Fertinorm-P®)
46 Myo-inositol and Melatonin in Pre-menopausal Women Completed NCT01115127 Phase 2, Phase 3
47 Thermosensitive Gels for the Vaginal Delivery of Sildenafil Citrate Completed NCT02766725 Phase 2, Phase 3 preparation F12 sildenafil in situ gel;preparation F2 sildenafil in situ gel;placebo gel
48 Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS Completed NCT01482286 Phase 3 Metformin
49 Extended Clomiphene Citrate Regimen in Women With Polycystic Ovary Syndrome Completed NCT02381184 Phase 2, Phase 3 clomiphene citrate
50 Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding (STOP-DUB) Completed NCT00114088 Phase 3

Search NIH Clinical Center for Anovulation

Cochrane evidence based reviews: anovulation

Genetic Tests for Anovulation

Anatomical Context for Anovulation

MalaCards organs/tissues related to Anovulation:

41
Ovary, Pituitary, Endothelial, Testes, Bone, Breast, Heart

Publications for Anovulation

Articles related to Anovulation:

(show top 50) (show all 342)
# Title Authors Year
1
Authors' reply re: Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. ( 29226510 )
2018
2
C-type natriuretic peptide: a link between hyperandrogenism and anovulation in a mouse model of polycystic ovary syndrome. ( 29739821 )
2018
3
Re: Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. ( 29210151 )
2018
4
Altered expression of IL-1I^, IL-1RI, IL-1RII, IL-1RA and IL-4 could contribute to anovulation and follicular persistence in cattle. ( 29334661 )
2018
5
C-Reactive protein in relation to fecundability and anovulation among eumenorrheic women. ( 29317123 )
2018
6
High level of C-type natriuretic peptide induced by hyperandrogen-mediated anovulation in polycystic ovary syndrome mice. ( 29535265 )
2018
7
Dietary minerals, reproductive hormone levels and sporadic anovulation: associations in healthy women with regular menstrual cycles. ( 29673411 )
2018
8
Lysyl oxidase blockade ameliorates anovulation in polycystic ovary syndrome. ( 30272163 )
2018
9
Oligo-anovulation is not a rarer feature in women with documented endometriosis. ( 30316441 )
2018
10
Gonadotrophins versus clomifene citrate with or without intrauterine insemination in women with normogonadotropic anovulation and clomifene failure (M-OVIN): a randomised, two-by-two factorial trial. ( 29273245 )
2017
11
Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. ( 28544572 )
2017
12
Re: Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. ( 28815934 )
2017
13
Rates of Anovulation in Adolescents and Young Adults with Moderate to Severe Primary Dysmenorrhea and Those without Primary Dysmenorrhea. ( 29017868 )
2017
14
Treatment strategies for women with WHO group II anovulation: systematic review and network meta-analysis. ( 28143834 )
2017
15
Prohibitin-induced obesity leads to anovulation and polycystic ovary in mice. ( 28432106 )
2017
16
Authors' reply re: Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. ( 28815914 )
2017
17
Phase III trial comparing the efficacy and safety of recombinant- or urine-derived human chorionic gonadotropin for ovulation triggering in Japanese women diagnosed with anovulation or oligo-ovulation and undergoing ovulation induction with follitropin-alfa. ( 29259450 )
2017
18
Reply: Metformin for women with hyperandrogenic anovulation. ( 26906091 )
2016
19
Subfertility in rheumatoid arthritis is often unexplained or caused by anovulation. ( 27723275 )
2016
20
Serum caffeine and paraxanthine concentrations and menstrual cycle function: correlations with beverage intakes and associations with race, reproductive hormones, and anovulation in the BioCycle Study. ( 27225433 )
2016
21
Metformin for women with hyperandrogenic anovulation. ( 26906093 )
2016
22
Low-dose aspirin and sporadic anovulation in the EAGeR randomized trial. ( 27754808 )
2016
23
Dairy Food Intake Is Associated with Reproductive Hormones and Sporadic Anovulation among Healthy Premenopausal Women. ( 27881593 )
2016
24
Effect of a low glycemic diet in patients with polycystic ovary syndrome and anovulation - a randomized controlled trial. ( 29734548 )
2016
25
Role of cortisol and superoxide dismutase in psychological stress induced anovulation. ( 26393311 )
2015
26
Prevalence of conditions causing chronic anovulation and the proposed algorithm for anovulation evaluation. ( 25772812 )
2015
27
Non-reproductive Effects of Anovulation: Bone Metabolism in the Luteal Phase of Premenopausal Women Differs between Ovulatory and Anovulatory Cycles. ( 26726266 )
2015
28
Loss of Body Fat and Associated Decrease in Leptin in Early Lactation Are Related to Shorter Duration of Postpartum Anovulation in Healthy US Women. ( 25596410 )
2015
29
Infertility in Female Mice with a Gain-of-Function Mutation in the Luteinizing Hormone Receptor Is Due to Irregular Estrous Cyclicity, Anovulation, Hormonal Alterations, and Polycystic Ovaries. ( 26040673 )
2015
30
Factors associated with nonresponse to ovulation induction using letrozole among women with World Health Organization group II anovulation. ( 26157297 )
2015
31
Increased androgen, anti-MA1llerian hormone, and sporadic anovulation in healthy, eumenorrheic women: a mild PCOS-like phenotype? ( 24606085 )
2014
32
The role of AMH in anovulation associated with PCOS: a hypothesis. ( 24770999 )
2014
33
Cost-effectiveness analysis on the use of rFSH + rLH for the treatment of anovulation in hypogonadotropic hypogonadal women. ( 25028553 )
2014
34
Accounting for Anovulation and Vaginal Thinning During Depot Medroxyprogesterone Acetate Use. ( 25217405 )
2014
35
Terms and thresholds for the ultrasound evaluation of the ovaries in women with hyperandrogenic anovulation. ( 24516084 )
2014
36
Serum zonulin is elevated in women with polycystic ovary syndrome, and correlates with insulin resistance and severity of anovulation. ( 25336505 )
2014
37
Lactational anovulation in mice results from a selective loss of kisspeptin input to GnRH neurons. ( 24169550 )
2014
38
Willingness to pay for ovulation induction treatment in case of WHO II anovulation: a study using the contingent valuation method. ( 25328385 )
2014
39
Examining the ovaries by ultrasound for diagnosing hyperandrogenic anovulation: updating the threshold for newer machines. ( 24534278 )
2014
40
Pregnancy complications and metabolic disease in women with clomiphene citrate-resistant anovulation randomized to receive laparoscopic electrocautery of the ovaries or ovulation induction with gonadotropins: a 10-year follow-up. ( 24268702 )
2014
41
Individual and combined effects of anovulation and cytological endometritis on the reproductive performance of dairy cows. ( 24996269 )
2014
42
Visceral adiposity index (VAI) is related to the severity of anovulation and other clinical features in women with polycystic ovary syndrome. ( 24601936 )
2014
43
Depressive symptoms and their relationship with endogenous reproductive hormones and sporadic anovulation in premenopausal women. ( 25453349 )
2014
44
Assessment of anovulation in eumenorrheic women: comparison of ovulation detection algorithms. ( 24875398 )
2014
45
Counting ovarian follicles: updated threshold for diagnosis of hyperandrogenic anovulation. ( 25088509 )
2014
46
The influence of sporadic anovulation on hormone levels in ovulatory cycles. ( 23589536 )
2013
47
Clinical review: Adolescent anovulation: maturational mechanisms and implications. ( 23913942 )
2013
48
Loss of LH-induced down-regulation of anti-MA1llerian hormone receptor expression may contribute to anovulation in women with polycystic ovary syndrome. ( 23321213 )
2013
49
British Fertility Society. 'Ovulation induction in WHO Type 1 anovulation: Guidelines for practice'. Produced on behalf of the BFS Policy and Practice Committee. ( 24245485 )
2013
50
The M-OVIN study: does switching treatment to FSH and / or IUI lead to higher pregnancy rates in a subset of women with world health organization type II anovulation not conceiving after six ovulatory cycles with clomiphene citrate - a randomised controlled trial. ( 24160333 )
2013

Variations for Anovulation

Expression for Anovulation

Search GEO for disease gene expression data for Anovulation.

Pathways for Anovulation

Pathways related to Anovulation according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.37 CGA FSHB GNRH1 IGF1
2
Show member pathways
12.16 CGA INS LEP PRL
3
Show member pathways
11.91 CGA FSHB IGF1 INS LEP
4 11.84 CGA FSHB FSHR
5 11.73 IGF1 INS LEP
6 11.24 INS LEP PRL
7 11.15 CGA CYP19A1 IGF1
8 11.04 CYP19A1 FSHR
9
Show member pathways
11 CRP LEP
10 10.89 CGA CYP19A1 FSHB FSHR
11 10.87 FSHB FSHR
12 10.86 BMP15 CGA CYP19A1 FSHB FSHR IGF1
13 10.71 GNRH1 SHBG
14 10.37 CGA FSHB FSHR GNRH1

GO Terms for Anovulation

Cellular components related to Anovulation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 BMP15 CGA CRP FSHB GNRH1 IGF1
2 extracellular region GO:0005576 9.32 BMP15 CGA CRP FSHB GNRH1 IGF1
3 endosome lumen GO:0031904 9.26 INS PRL
4 follicle-stimulating hormone complex GO:0016914 9.16 CGA FSHB

Biological processes related to Anovulation according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.92 CRP FSHB IGF1 INS
2 positive regulation of cell migration GO:0030335 9.81 CGA FSHB IGF1 INS
3 cellular protein metabolic process GO:0044267 9.8 BMP15 IGF1 INS PRL
4 positive regulation of cell proliferation GO:0008284 9.8 CGA FSHB IGF1 INS LEP PRL
5 positive regulation of MAPK cascade GO:0043410 9.78 IGF1 INS LEP
6 response to ethanol GO:0045471 9.74 GNRH1 LEP PRL
7 regulation of multicellular organism growth GO:0040014 9.64 IGF1 PRL
8 positive regulation of mitotic nuclear division GO:0045840 9.63 IGF1 INS
9 positive regulation of JAK-STAT cascade GO:0046427 9.63 LEP PRL
10 peptide hormone processing GO:0016486 9.62 CGA FSHB
11 positive regulation of glycolytic process GO:0045821 9.61 IGF1 INS
12 uterus development GO:0060065 9.6 CYP19A1 FSHR
13 positive regulation of glycogen biosynthetic process GO:0045725 9.59 IGF1 INS
14 positive regulation of insulin receptor signaling pathway GO:0046628 9.58 INS LEP
15 regulation of osteoclast differentiation GO:0045670 9.58 FSHB FSHR
16 gonad development GO:0008406 9.56 CGA FSHR
17 female pregnancy GO:0007565 9.56 FSHB GNRH1 LEP PRL
18 negative regulation of blood vessel diameter GO:0097756 9.55 CRP INS
19 ovulation cycle GO:0042698 9.54 GNRH1 PRL
20 female gonad development GO:0008585 9.54 AMHR2 CYP19A1 FSHR
21 negative regulation of lipid storage GO:0010888 9.52 CRP LEP
22 bone mineralization involved in bone maturation GO:0035630 9.48 IGF1 LEP
23 Sertoli cell proliferation GO:0060011 9.46 FSHB FSHR
24 follicle-stimulating hormone signaling pathway GO:0042699 9.43 FSHB FSHR
25 positive regulation of steroid biosynthetic process GO:0010893 9.4 CGA FSHB
26 female gamete generation GO:0007292 9.33 BMP15 FSHB FSHR
27 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.26 FSHR IGF1 INS LEP
28 regulation of signaling receptor activity GO:0010469 9.23 BMP15 CGA FSHB GNRH1 IGF1 INS

Molecular functions related to Anovulation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin receptor binding GO:0005158 9.26 IGF1 INS
2 hormone activity GO:0005179 9.17 CGA FSHB GNRH1 IGF1 INS LEP
3 insulin-like growth factor receptor binding GO:0005159 9.16 IGF1 INS
4 follicle-stimulating hormone activity GO:0016913 8.96 CGA FSHB

Sources for Anovulation

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....